INTRODUCTION {#s1}
============

The mitochondrial genome encodes 13 protein subunits of the respiratory chain complexes, as well as ribosomal and transfer RNAs required for their translation. The remaining proteins required for mitochondrial structure and function are encoded by the nuclear genome. Mutations in nuclear genes involved in the maintenance of the mitochondrial genome lead to deletions or depletion of mitochondrial DNA (mtDNA). The loss of mtDNA leads to respiratory chain dysfunction causing a number of progressive multisystemic neuromuscular disorders (for review, see [@PIERCEMCS001107C1]). Genetic heterogeneity and the overlapping and complex nature of the phenotypes make it difficult to predict which gene will be mutated in an affected individual.

Mitochondrial DNA depletion syndrome 7 (MTDPS7; OMIM 271245) is associated with a variable phenotype that may include infantile or adult-onset spinocerebellar ataxia, ophthalmoplegia, encephalopathy, seizures, and hepatic failure. Infantile onset spinocerebellar ataxia (IOSCA) is one of the phenotypes seen in MTDPS7. It is characterized by normal development for approximately the first year of life followed by the development of muscle hypotonia, ataxia, ophthalmoplegia, optic atrophy, hearing loss, sensory axonal neuropathy, epilepsy, and female hypogonadism ([@PIERCEMCS001107C11]). First described in Finland, IOSCA was shown to be caused by homozygosity for a founder mutation in the *C10orf2* gene (c.1708A\>G, p.Y508C) ([@PIERCEMCS001107C17]). *C10orf2* encodes the mitochondrial DNA helicase Twinkle, which is essential for mtDNA replication ([@PIERCEMCS001107C14]). A limited number of additional *C10orf2* mutations have since been reported as causing IOSCA, as well as milder and more severe recessive phenotypes ([@PIERCEMCS001107C6]; [@PIERCEMCS001107C22]; [@PIERCEMCS001107C2]; [@PIERCEMCS001107C4]; [@PIERCEMCS001107C8]; [@PIERCEMCS001107C3]; [@PIERCEMCS001107C21]; [@PIERCEMCS001107C16]; [@PIERCEMCS001107C20]). The identification of new cases will help to define the spectrum of *C10orf2* mutations that result in recessive disease and provide a more complete understanding of the range of phenotypes caused by these mutations. We describe a 13-yr-old girl with clinical features of IOSCA and compound heterozygosity for novel variants in *C10orf2*.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

A 13-year-old female was evaluated for her history of ataxia, severe hearing loss, optic atrophy, and peripheral neuropathy ([Fig. 1](#PIERCEMCS001107F1){ref-type="fig"}A). She was the first child of unrelated American parents of European descent, born healthy after a normal pregnancy and delivery; birth weight was 3.997 kg and length was 57 cm. She developed normally for the first 8--9 mo, sitting and crawling by 6 mo of age and pulling up at 7.5 mo. Hypotonia was noted by 10 mo of age. Infantile spasms occurred at 12 mo of age, with electroencephalography (EEG) indicating modified hypsarrhythmia. Seizures resolved 6--8 wk after treatment with topiramate and pyridoxine, which was added empirically, and have not recurred. EEG results were normal at 5 and 13 yr of age. At the time of the seizures, levels of urine organic acids, ammonia, plasma amino acids, and serum lactate and pyruvate were normal. Development slowed after the onset of seizures. Walking was achieved at age 3 yr, but balance was poor. Hearing impairment became evident at 3 yr of age and auditory neuropathy was diagnosed. Optic neuropathy was diagnosed at 5 yr of age. Electroretinography was normal. Evaluation for additional neuropathy identified peripheral neuropathy in the lower legs and feet. Nerve conduction velocities performed at 10 yr of age indicated mild axonopathy with decreased velocity and reduced amplitude. Brain imaging studies were normal as determined by magnetic resonance imaging at 12 mo, 3 yr, and 4.5 yr of age, and computed tomography (CT) scan at 10 yr of age. Additional laboratory testing included normal blood urea nitrogen, creatinine, total serum protein, bilirubin, albumin, liver transaminases, long chain fatty acids, plasma acylcarnitine profile, serum α-fetoprotein, metabolic screen, and spinal fluid lactate (1.6 mmol/L; normal range 0.8--2.4). Initial genetic analysis revealed a normal 46,XX karyotype and normal results from microarray analysis using the Human SNP 6.0 array (Affymetrix), sequencing of *GJB2* (encoding connexin 26) and *POLG*, and sequencing of the mitochondrial genome. Results of a 103-gene epilepsy panel test revealed maternally inherited variants of unknown significance (VUSs) in *TSEN54* and *CNTNAP2* and a paternally inherited VUS in *MAGI2* (<http://www.ggc.org/diagnostic/tests-costs/test-finder/ngs-epilepsy-seizure-panel.html>).

![Compound heterozygosity for *C10orf2* mutations. (*A*) Pedigree of family of affected patient II-1; *C10orf2* genotypes are indicated. (*B*) Validation by Sanger sequencing of *C10orf2* mutations identified by exome sequencing. Codon changes are indicated in red. (*C*) Domain architecture of the Twinkle protein. (*D*) Protein sequence alignment of orthologs of the Twinkle protein, encoded by *C10orf2*, showing the region surrounding the mutated arginine residue, R302 (indicated in red).](PierceMCS001107_F1){#PIERCEMCS001107F1}

Examination of the patient at age 13 revealed ataxia, pes cavus, decreased vibratory sensation and proprioception, hyporeflexia, ophthalmoplegia without ptosis, and bilateral optic atrophy. No abnormal pigment was present in the retina. She walks on the outside of the foot, with gait studies showing a mild increased femoral anteversion, and suffers frequent falls as a result of ataxia; she uses a wheelchair for long distances. She has mild intellectual disability, requiring special education services in a self-contained classroom for students with orthopedic impairment. Primary amenorrhea and lack of breast development prompted an endocrine evaluation, which revealed elevated follicle-stimulating hormone (FSH; \>86 mIU/mL; normal range 0.7--11.0) and luteinizing hormone (LH; 18.76 mIU/mL; normal range 0.04--10.80). A uterus and ovaries were undetected by ultrasound, consistent with hypergonadotropic hypogonadism. Recently, the patient has experienced two viral illnesses that have been associated with episodes of worsening ocular paralysis. The two parents and a younger brother have none of the above signs.

Whole-Exome Sequencing {#s2b}
----------------------

Genomic DNA samples from all family members were evaluated by whole-exome sequencing. The presence of a single affected female individual in this family is consistent with autosomal recessive inheritance or with a dominant de novo mutation. We filtered variants of the proband to identify potentially damaging homozygous, compound heterozygous, and de novo variants. Only one result matched any of these criteria: the proband was compound heterozygous for *C10orf2* c.333delT (p.L112Sfs\*3) at Chr 10:102,748,300, inherited from her father, and *C10orf2* c.904C\>T (p.R302W) at Chr 10:102,748,871, inherited from her mother ([Tables 1](#PIERCEMCS001107TB1){ref-type="table"} and [2](#PIERCEMCS001107TB2){ref-type="table"}; [Fig. 1](#PIERCEMCS001107F1){ref-type="fig"}A,B). The unaffected brother is heterozygous for *C10orf2* c.904C\>T. Among 60,628 individuals with whole-exome data in the Exome Aggregation Consortium (ExAC) database, one individual carried *C10orf2* c.904C\>T and none carried *C10orf2* c.333delT.

###### 

C10orf*2* (NM_021830.4) variants

  Chr:position GRCh37(hg19)    HGVS cDNA  HGVS protein     Type of variant   Predicted effect                Genotype     Parent of origin
  --------------------------- ----------- ---------------- ----------------- ---------------------------- -------------- ------------------
  10:102,748,300               c.333delT  p.(L112Sfs\*3)   Deletion          Frame shift and truncation    Heterozygous        Father
  10:102,748,871               c.904C\>T  p.(R302W)        Substitution      Missense                      Heterozygous        Mother

HGVS, Human Genome Variation Society; cDNA, complementary DNA.

*C10orf2* encodes the Twinkle DNA helicase, which unwinds double-stranded DNA and functions with polymerase γ (POLG) during mtDNA replication ([@PIERCEMCS001107C14]). As the only replicative helicase in mammalian mitochondria, Twinkle is essential for mtDNA replication ([@PIERCEMCS001107C15]). Twinkle contains three functional domains: an amino-terminal primase, a linker region, and a carboxy-terminal helicase ([Fig. 1](#PIERCEMCS001107F1){ref-type="fig"}C; [@PIERCEMCS001107C23]). The Twinkle p.L112Sfs\*3 variant is predicted to yield a truncated protein that would lack most of the primase domain and all of the linker and helicase domains and is unlikely to be functional. The missense variant p.R302W is predicted to be damaging by PolyPhen-2 (score 1.00) and SIFT Blink (*P* = 0.00). Arginine at residue 302 is conserved in virtually all mammals and arginine or similarly charged lysine is conserved in virtually all vertebrates ([Fig. 1](#PIERCEMCS001107F1){ref-type="fig"}D). Bulky hydrophobic residues such as tryptophan are never present at this position.

Structural Modeling of Twinkle p.R302W {#s2c}
--------------------------------------

We investigated the possible consequences of the Twinkle p.R302W missense substitution by examining the three-dimensional structure of bacteriophage T7 primase-helicase gp4, a Twinkle ortholog. Studies of prokaryotic primase-helicase enzymes suggest that Twinkle proteins likely form hexameric or heptameric ring structures, in which the tightly packed ring of helicase domains is topped with a more loosely arranged crown of primase domains ([Fig. 2](#PIERCEMCS001107F2){ref-type="fig"}; [@PIERCEMCS001107C25]). The Twinkle residue p.R302 is near the carboxy-terminal end of the primase domain. The gp4 residue p.E200, orthologous to Twinkle p.R302, is on the outer surface of the primase ring, facing down toward the helicase ring. The p.R302W substitution would place a bulky hydrophobic residue, which is most often found buried in the hydrophobic protein core, on the protein surface, possibly affecting the protein\'s stability or solubility. Interestingly, the mutation p.R303W, which replaces the adjacent arginine residue with a tryptophan and is also found in human patients, results in reduced thermostability of the mutant protein ([@PIERCEMCS001107C12]).

![Crystal structure of the Twinkle ortholog gp4 from T7 bacteriophage: Two subunits of the heptameric primase-helicase gp4 (PDB ID 1Q57) are shown in pink and green; remaining subunits are shown in gray. Helicase domains compose the bottom ring, and primase domains of three subunits (green, pink, and one gray) appear to hover on top. The linker region of the pink subunit is shown in dark pink surface representation; its interior surface appears black where visible; the linker region of the green subunit is light green. All other domains and subunits are shown as cartoons. The residue corresponding to the p.R302W mutation in this report is shown in black spheres and residues corresponding to other Twinkle mutations causing recessive disease are shown as purple spheres; residues are indicated with the Twinkle residue numbers. The catalytic residue p.R609 is shown in red sticks. The residue corresponding to p.P83 was not included in the crystallized protein.](PierceMCS001107_F2){#PIERCEMCS001107F2}

Structural Modeling of Twinkle Mutations Causing Recessive Disease {#s2d}
------------------------------------------------------------------

Thirteen additional Twinkle missense mutations have been previously identified as causing recessive disease. For comparison, we also mapped the sites of these mutations onto the structure of gp4 ([Fig. 2](#PIERCEMCS001107F2){ref-type="fig"}). Strikingly, six of the affected residues flank the linker region of the adjacent subunit. The linker is involved in oligomerization and required for helicase activity ([@PIERCEMCS001107C15]). In particular, the residues orthologous to p.L456, p.T457, and p.R463 are in helices that appear to support the path of the linker. Consistent with this, structural modeling previously suggested that p.T457 plays a role in subunit interactions ([@PIERCEMCS001107C22]). As we previously reported, the residue orthologous to p.Y507 is predicted to interact directly with the linker of the neighboring subunit ([@PIERCEMCS001107C16]), as does the adjacent residue orthologous to p.Y508. In addition, as we previously noted, the residues orthologous to p.R391 and p.Y441 interact with each other and are proximal to the linker domain of their own subunit. Thus, eight of the mutations may disrupt the position or interactions of the linker region, which is critical for flexibility and closure of the oligomeric ring structure ([@PIERCEMCS001107C25]). One of the remaining mutations, p.N585S, is likely to impact the position of a critical catalytic residue and thus affect enzyme activity ([@PIERCEMCS001107C16]). Possible effects of the other mutations, including p.R302W and three others in the primase domain, include impacts on subunit stability or on single-stranded DNA binding, which is necessary for optimal helicase activity and for which the primase domain is required ([@PIERCEMCS001107C9]).

DISCUSSION {#s3}
==========

Recessive conditions caused by mutations in Twinkle have been grouped together as MTDPS7. The variable phenotypes of MTDPS7 include IOSCA ([@PIERCEMCS001107C17]; [@PIERCEMCS001107C2]; [@PIERCEMCS001107C8]; [@PIERCEMCS001107C3]; [@PIERCEMCS001107C20]), the more severe hepatocerebral syndrome ([@PIERCEMCS001107C6]; [@PIERCEMCS001107C22]; [@PIERCEMCS001107C4]; [@PIERCEMCS001107C21]), involving early liver damage, and the less severe Perrault syndrome (OMIM 233400), which is limited to hearing loss, female hypergonadotropic hypogonadism, and ataxia ([Fig. 3](#PIERCEMCS001107F3){ref-type="fig"}; [@PIERCEMCS001107C16]). Mutations leading to any of these phenotypes can cause histological changes detectable by muscle biopsy. However, mtDNA depletion has only been detected in cases of IOSCA and hepatocerebral syndrome by examining mtDNA copy number in brain and liver; mtDNA depletion was not detectable in muscle ([@PIERCEMCS001107C7]). Muscle mitochondrial respiratory chain enzyme activities are normal in cases of IOSCA and Perrault syndrome. The phenotype and clinical course of the patient described here are most similar to IOSCA, as described in patients who are homozygous for the Finnish founder allele. The follow-up of a cohort of Finnish IOSCA patients into adulthood indicates that the majority of patients develop severe epilepsy and many develop psychiatric symptoms ([@PIERCEMCS001107C13]). The use of certain antiseizure medications, such as valproate, can lead to dangerous liver toxicity in IOSCA patients ([@PIERCEMCS001107C13]), as seen in other mtDNA depletion syndromes, such as *POLG* disorders ([@PIERCEMCS001107C10]).

![Phenotypic features of cases with recessive IOSCA, hepatocerebral syndrome, and Perrault syndrome caused by mutations in the *C10orf2* gene. Colored symbols indicate the presence of clinical signs and laboratory findings in patients with each genotype. Patients homozygous for p.T457I and p.F395L mutations had abnormal eye movements (^a^). The p.R29\*/p.Y508C compound heterozygous patient had a dysconjugate gaze (^b^). Ophthalmic signs included optic atrophy (^c^) and delayed or absent visual-evoked potentials (^d^). Seizure activity was suspected in the p.R29\*/p.Y508C compound heterozygous patient (^e^). In some patients lactate was mildly or inconsistently elevated (^f^). Patients homozygous for the p.Y508C mutation had elevated liver enzymes only when treated with valproate (^g^). Abnormal muscle biopsies showed fiber type grouping, atrophy of type II fibers, and/or COX-negative fibers (^h^). Abnormal nerve biopsies showed loss of myelinated nerve fibers (^i^). The p.T487I/c.1485-1G\>A compound heterozygous patients carried the heteroplasmic mtDNA deletion m.8470_13446del4977, which is commonly associated with progressive external ophthalmoplegia (^j^). Eur, European; Fin, Finnish; Eng, English; Trk, Turkish; Ind, Indian; Kor, Korean; Alg, Algerian; Pak, Pakistani; Gre, Greek; Jpn, Japanese; n.a., not available.](PierceMCS001107_F3){#PIERCEMCS001107F3}

Including the case reported here, 12 *C10orf2* genotypes have been reported as causing recessive disease ([Fig. 3](#PIERCEMCS001107F3){ref-type="fig"}), with half of these genotypes causing the moderate IOSCA phenotype. With the exception of the Finnish founder allele, p.Y508C, homozygous or compound heterozygous *C10orf2* mutations have been identified in single cases or small families of many different ancestries. Dominant progressive external ophthalmoplegia type 3 (PEOA3, OMIM 609286) is also caused by mutations in *C10orf2* and at least 40 causative mutations have been identified ([@PIERCEMCS001107C16]). There is no overlap between the mutations causing dominant and recessive phenotypes.

Understanding and predicting the functional impact of individual Twinkle variants is particularly challenging. Although many of the mutations causing recessive phenotypes are likely to impact the position of the linker region, many of the mutations causing dominant PEOA3 are also clustered within or near the linker region. In several cases mutation of adjacent amino acids causes distinct recessive and dominant phenotypes ([@PIERCEMCS001107C16]). Recent structural modeling and biochemical analysis of the Finnish founder allele p.Y508C suggests that the substitution disrupts the coupling between NTP hydrolysis and single-stranded DNA binding and translocation ([@PIERCEMCS001107C18]), which is important for the sequential and cooperative catalytic activity of the different subunits within the ring structure ([@PIERCEMCS001107C24]). However, a thorough evaluation of 20 mutations of Twinkle, causing both dominant and recessive disease, found no simple relationship between perturbations of the biochemical properties of Twinkle and the severity of clinical phenotypes caused by the mutations ([@PIERCEMCS001107C12]). Thus, subtle changes in enzyme activity, structure, or stability may be enough to cause disease, with the clinical outcome influenced by the specific combination of alleles.

The progressive multisystemic phenotype of our patient led to the suspicion of a mitochondrial disorder; however, biochemical indicators in blood, urine, and spinal fluid were lacking. The inability to detect mtDNA or respiratory chain defects in muscle biopsies of IOSCA patients and the inconsistent elevation of serum or spinal fluid lactate make it challenging to reach a definitive diagnosis of mitochondrial dysfunction in these cases. In addition, the features of IOSCA overlap considerably with those of other multisystemic disorders, making it difficult to predict a genetic cause. Our results emphasize the utility of whole-exome sequencing for the genetic diagnosis of a complex multisystemic disorder and identified novel Twinkle mutations as the cause of IOSCA. Because of the complex phenotypes of mitochondrial disorders, disease allele identification by massively parallel sequencing is now the gold standard for evaluation ([@PIERCEMCS001107C19]).

METHODS {#s4}
=======

Genomics {#s4a}
--------

Genomic DNA was isolated from blood and evaluated by whole-exome sequencing as previously described with some modifications ([@PIERCEMCS001107C26]; [@PIERCEMCS001107C5]). Genomic DNA libraries were captured with NimbleGen VCRome v2.1 ([@PIERCEMCS001107C27]), and then sequenced on an Illumina HiSeq 2500. Paired-end sequence reads (2 × 100 bp) were collected, filtered for quality, and aligned to exome targets using Burrows--Wheeler alignment (BWA), and then genotypes were called using the Genome Analysis Toolkit (GATK). At least 97.13% of targeted bases were covered at ≥8× in all family members ([Table 2](#PIERCEMCS001107TB2){ref-type="table"}). Artifacts and common variants were excluded by comparison with \>1000 exomes previously sequenced in our laboratory and with frequencies in the ExAC database (<http://exac.broadinstitute.org>), the NHLBI Grand Opportunity (GO) Exome Sequencing Project (<https://esp.gs.washington.edu>), and the 1000 Genomes Project (<http://www.1000genomes.org>). Variants were classified by predicted function as nonsense mutations, frameshift mutations, variants within 1 bp of a splice site, and missense variants. Missense mutations were evaluated for predicted effect on protein function based on conservation at the variant site and by using in silico tools PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) and SIFT (Sorting Intolerant From Tolerant; <http://sift.bii.a-star.edu.sg>). All missense variants predicted to be damaging and all variants predicted to lead to protein truncation were retained as candidate alleles. Candidate variants were validated by Sanger sequencing, and then tested for cosegregation with the phenotype in all family members. Primers used for validation were 5′-ccagtgttgcctgtaactgc-3′ and 5′-ccaagggaagacaagactgc-3′ for *C10orf2* c.333delT and 5′-agtcgtcgagatgctgaggt-3′ and 5′-ggccaaccttcttttcaaca-3′ for *C10orf2* c.904C\>T.

###### 

Exome sequencing results and variant filtering

                                                  II-1         II-2         I-1          I-2
  ------------------------------------------- ------------ ------------ ------------ ------------
  Total number of reads                        79,999,788   72,975,641   85,959,236   78,811,279
  \% of mapped reads                             98.25        97.97        98.66        98.66
  \% of targeted bases covered at ≥8×            96.73        96.67        97.13        97.23
  \% of targeted bases covered at ≥20×           92.42        91.59        94.14        93.93
  Average coverage, ×                            79.02        71.07        99.65        89.97
  All coding and splice variants                 22,908       22,671       23,073       22,257
  Rare variants^a^                                264          232          267          246
  Predicted damaging to protein function^b^        83           71           76           70
  De novo damaging variants                        0            1            --           --
  Damaging variants fitting recessive model        2            --           --           --

^a^Variants were excluded if minor allele frequency was ≥0.001 in the 1000 Genomes Project or the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project or if there were more than 60 carriers on the Exome Aggregation Consortium (ExAC) database.

^b^Variants predicted damaging to protein function were truncating mutations, splice site mutations predicted to alter transcripts, and missense variants with PolyPhen-2 score of ≥0.8 and SIFT score of ≤0.05.

Protein Structure Modeling {#s4b}
--------------------------

Structural roles of Twinkle residues were predicted by comparison with the structure of bacteriophage T7 primase-helicase gp4 (PDB 1Q57). Orthologous residues were identified by amino acid sequence alignment with ClustalW2. Structures were visualized and cartoons rendered using the PyMOL Molecular Graphics System, version 1.5.0.4, Schrödinger, LLC.
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======================

Data Deposition and Access {#s5a}
--------------------------

Our patient consent does not permit us to make patient sequence data publicly available. The *C10orf2* variants identified in this study have been deposited in ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) under the accession numbers SCV000267647 and SCV000267648 and in the Leiden Open Variation Database (LOVD) (<http://databases.lovd.nl/shared/genes/C10orf2>) under variant IDs 0000091271 and 0000091272.
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